- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Undervalued based on future growth
Australian Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Clinuvel Pharmaceuticals
Market Cap: AU$578.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.54
7D
8.9%
1Y
-19.8%
EZZ Life Science Holdings
Market Cap: AU$102.8m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.18
7D
-3.1%
1Y
-24.8%